title: [MyD88 L265P mutation and B cell tumor].
abstract: Myeloid differentiation factor (MyD88) is an important adaptor protein mediating the signal transduction of most Toll-like receptors (TLR), interleukin-1 receptor (IL-1R) and interleukin-18 receptor (IL-18R) that play a key role to mediate innate immune response. Recently, activating of MYD88 L265 mutation has been reported in about of 90% lymphoplasmacytoid lymphoma/Waldenström's Macroglobulinemia, about of 29% activated type diffuse large B-cell lymphoma and other subtypes of B cell tumors demonstrating the MyD88 signaling plays an important role in B cell tumorigenesis, and inhibitors targeting MyD88 might become a new remedy for B cell tumors. In this review, the latest advances in the roles of MyD88 L265P mutation in B cell tumorigenesis were summarized.
authors.affiliation: Department of Hematology, Zhabei Branch of Changzheng Hospital, The Second Military Medical University, Shanghai 200070, China.
authors.forename: Hai-Min
authors.initials: HM
authors.lastname: Chen
authors.affiliation: Department of Hematology, Zhabei Branch of Changzheng Hospital, The Second Military Medical University, Shanghai 200070, China; Department of Hematology, Changzheng Hospital, The Second Military Medical Uuniversity, Shanghai 200003, China. E-mail: houjian@medmail.com.cn.
authors.forename: Jian
authors.initials: J
authors.lastname: Hou
mesh_terms: D063646:Carcinogenesis; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse; D009154:Mutation; D053594:Myeloid Differentiation Factor 88 / Q000235:genetics*; D015398:Signal Transduction
chemical_list: C507779:MYD88 protein, human; D053594:Myeloid Differentiation Factor 88